This is of particular note as the tau in DLBTau+ subjects exhibit a different PTM profile to AD tau. Our comprehensive proteomic analysis revealed notable proteome differences in the cortex between patients identified in this study as DLBTau+ and DLBTau−, including dysregulated proteins and pathways that distinguish the subgroups. The gene discussed is MAPT; the disease is Alzheimer disease.